報價延遲最少15分鐘:2025/06/20 09:39 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.9 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.04/--
|
|
企業價值
608.22M
|
| 資產負債 |
|
每股賬面淨值
-0.48
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
--
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/20 09:39 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Jyong Biotech Ltd is a science-driven biotechnology company based in Taiwan and is committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia (primarily Taiwan and mainland China). It has been dedicated to the research and development of new drugs with high safety and efficacy. It has been developing a series of drug candidates, including one core drug candidate at NDA stage, one clinical-stage key drug candidate and other preclinical-stage drug candidates. |